<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01163058</url>
  </required_header>
  <id_info>
    <org_study_id>ONC/OSS-01/2010</org_study_id>
    <nct_id>NCT01163058</nct_id>
  </id_info>
  <brief_title>Tyrosine Kinase Inhibitors In Metastatic Non Small Cell Lung Cancer</brief_title>
  <official_title>Retrospective Analysis Evaluating Molecular Factors of Primary Resistance to Tyrosine Kinase Inhibitors in Metastatic Non Small Cell Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the present retrospective study is to evaluate molecular factors of primary resistance
      to tyrosine kinase inhibitors in metastatic non small cell lung cancer (NSCLC) patients. The
      investigators assess first, the incidence of epidermal growth factor receptor (EGFR) and
      Kirsten ras sarcoma viral oncogene homolog (KRAS) mutations, SOS and hepatocyte growth factor
      (HGF) expression, anaplastic lymphoma kinase (ALK) translocation and expression and,
      secondly, the investigators correlate molecular markers with clinical features and outcome in
      terms of response rate, progression free survival and overall survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non small cell lung cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the incidence of EGFR (Epidermal growth factor ) and KRAS (Kirsten ras sarcoma viral oncogene homolog ) mutations in 300 NSCLC (non small cell lung cancer) patients treated with gefitinib or erlotinib</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigate the association of clinical features such as sex, age, smoking history and histology with oncogenic alterations.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        non small cell lung cancer patients treated with gefitinib or erlotinib
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of NSCLC (non small cell lung cancer) with
             available tumor tissue for mutational analysis

          -  Metastatic disease treated with gefitinib or erlotinib

          -  Presence of at least one measurable lesion according to RECIST criteria

        Exclusion Criteria:

          -  No tumor tissue available

          -  No clinical data available
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armando Santoro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20059</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2010</study_first_submitted>
  <study_first_submitted_qc>July 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2010</study_first_posted>
  <last_update_submitted>July 27, 2010</last_update_submitted>
  <last_update_submitted_qc>July 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Armando Santoro, MD</name_title>
    <organization>Istituto Clinico Humanitas</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

